SynapCon receives official German federal R&D certification for €5.8M innovation project

Certified under the German Research Allowance Act (FZulG) for AI and blockchain-enabled clinical trial infrastructure.

Announcement

SynapCon GmbH has received official certification under the German Research Allowance Act (FZulG), issued by the German federal certification authority.

The certified R&D project covers a total eligible development volume of approximately €5.8 million.

The project “BC+KI4CTMS” focuses on the development and validation of a next-generation Clinical Trial Management System integrating blockchain validation mechanisms and advanced AI models.

Strategic Scope of the Project

The certified project includes:

• Blockchain-based validation and audit traceability

• Federated learning for secure distributed analytics

• AI-driven retrospective data intelligence

• Bayesian modelling for structured decision support• End-to-end encrypted cloud architecture

The certification confirms the project’s technological novelty, technical risk and structured development framework under §2 FZulG criteria.

Strategic Impact

This milestone strengthens SynapCon’s position as a regulatory-compliant digital infrastructure provider for global clinical research.

The development enhances the EasyClin platform toward:

• AI-enabled clinical intelligence

• Tamper-evident validation layers

• Inspection-ready documentation workflows

• Scalable international deployment

The certification further validates SynapCon’s long-term R&D strategy and commitment to compliant innovation.

For further information, please contact us via the Investors section or explore our technology roadmap.